ClinicalTrials.gg
CompletedNCT05644977Updated May 2, 2025

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

A Phase 1 interventional study of Emraclidine and Placebo in Healthy Participants and Alzheimer's Disease Dementia, sponsored by AbbVie. Completed at 11 sites in United States. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-02.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2025, 1 year 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Alzheimer Disease by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Alzheimer Disease · AbbVie.

Enrollment
24th of 27
17 · median 210
Started
2022
with 1 other
Phase 1
7 of 27
none open now
Registered
23rd of 27
by date

Among the 27 studies in Alzheimer Disease by AbbVie, this one is the 24th largest by enrollment, is one of 2 that started in 2022, is one of 7 in phase 1, and was the 23rd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 27 studies in Alzheimer Disease by AbbVie is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Alzheimer Disease by AbbVie, or all of them as a file.
02

Study summary

The primary purpose of the study is to evaluate the safety and tolerability of emraclidine administered orally to healthy elderly participants in Part A (multiple ascending doses) and participants with dementia due to Alzheimer's disease (AD) in Part B.

03

Conditions studied

  • Healthy Participants
  • Alzheimer's Disease Dementia
04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohorts 1 to 5 (Part A)

  1. Male participants and female participants of nonchildbearing potential, ages 65 to 85 years, inclusive.
  2. Healthy as determined by medical evaluation, including medical and psychiatric history, physical and neurological examinations, , vital sign measurements, and laboratory test results, as evaluated by the investigator.
  3. of 17.5 to 32.0 kilograms per square meter (kg/m\^2), inclusive, and total body weight >45 kg (100 pounds [lb]) at Screening.
  4. Female participants will be of nonchildbearing potential, defined as follows:

    • Achieved status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause, and confirmed with a serum follicle-stimulating hormone level >40 international units per milliliter (IU/mL).
  5. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the full protocol.

Cohort 6 (Part B)

  1. Male participants and female participants of nonchildbearing potential, ages 55 to 90 years, inclusive.
  2. Have a clinical diagnosis of possible or probable Alzheimer's disease dementia according to the 2011 National Institute on Aging - Alzheimer's Association (NIA-AA) clinical criteria at the Screening Visit; diagnosis must be stable for at least 6 months prior to signing the ICF.
  3. Have a (MMSE) score of 8 through 26, inclusive, at the Screening Visit.
  4. Have prior neuroimaging evidence (Computed Tomography [CT] or Magnetic resonance imaging [MRI] completed within the 3 years prior to signing the ICF) collected during or subsequent to the onset of dementia symptoms to rule out other central nervous system disorders that could account for the dementia syndrome.
  5. Currently receiving oral symptomatic treatment for dementia (i.e., cholinesterase inhibitor and/or memantine), must have been on a stable regimen for at least 6 weeks prior to signing ICF and be willing to maintain a stable dose for the duration of the trial.
  6. Body mass index of 17.5 to 40.0 kg/m2, inclusive, and total body weight >45 kg (100 lb) at Screening.

Exclusion criteria

Exclusion Criteria:

All Cohorts

  1. "Yes" responses for any of the following items on the C-SSRS (within the past 6 months):

    • Suicidal Ideation Item 4 (Active Suicidal Ideation with Some Intent to Act, without Specific Plan)
    • Suicidal Ideation Item 5 (Active Suicidal Ideation with Specific Plan and Intent) "Yes" responses for any of the following items on the C-SSRS (within past 2 years):
    • Any of the Suicidal Behavior items (Actual Attempt, Interrupted Attempt, Aborted Attempt, Preparatory Acts or Behavior). Serious risk of suicide in the opinion of the investigator is also exclusionary.
  2. Diagnosis of moderate to severe substance or alcohol-use disorder (excluding nicotine or caffeine) as per , Fifth Edition (DSM-5) criteria within 12 months prior to signing the ICF.
  3. Positive drug screen or a positive test for alcohol at Screening or Baseline Visits.
  4. Any of the following clinical laboratory test results at the Screening Visit (as assessed by the central laboratory) and at Check-in (Day -1; as assessed by the local laboratory), and confirmed by a single repeat measurement, if deemed necessary:

    • (AST) or alanine aminotransferase (ALT) ≥2.0 × upper limit normal ()
    • Total >1.5 × ULN. If Gilbert's syndrome is suspected, total bilirubin >1.5 × ULN is acceptable if the conjugated or direct bilirubin fraction is \<20% of total bilirubin.

Cohorts 1 to 5 (Part A)

  1. Current or past history of significant pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine (including diabetes mellitus), (except for basal cell carcinoma of the skin and cervical carcinoma in situ, at the discretion of the investigator), hematological, immunological, neurological, or psychiatric disease that, in the opinion of the investigator or medical monitor, could compromise either participant safety or the results of the trial.
  2. Current or past history of significant cardiovascular disease.
  3. Estimated \<60 milliliters per minute (mL/min)/1.73 m\^2, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI 2021) equation at the Screening Visit or Check-in (Day -1).

Cohort 6 (Part B)

  1. Has either of the following:

    • History of major depressive episode with psychotic features during the 12 months prior to signing the ICF
    • History of a diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder
  2. Has evidence of a neurological disorder other than possible or probable Alzheimer's disease such as, but not limited to, the following:

    • History of ischemic stroke within 12 months prior to signing the ICF or any evidence of hemorrhagic stroke
    • History of cerebral amyloid angiopathy, epilepsy, or central nervous system neoplasm
  3. Estimated glomerular filtration rate \<60 mL/min/1.73 m2, as calculated using the CKD-EPI 2021 equation the Screening Visit.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Part A: Cohort 1: Emraclidine Dose 1

    Participants will receive emraclidine dose 1 or emraclidine-matching placebo tablets, orally, once daily (QD) up to Day 14.

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Part A: Cohort 2: Emraclidine Dose 2

    Participants will receive emraclidine dose 2 or emraclidine-matching placebo tablets, orally, QD up to Day 14.

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Part A: Cohort 3: Emraclidine Dose 3

    Participants will receive emraclidine dose 3 or emraclidine-matching placebo tablets, orally, QD up to Day 14.

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Part A: Cohort 4: Emraclidine Dose 4

    Participants will receive emraclidine dose 4 or emraclidine-matching placebo tablets, orally, QD up to Day 14.

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Part A: Cohort 5: Emraclidine Dose 5

    Participants will receive emraclidine dose 5 or emraclidine-matching placebo tablets, orally, QD up to Day 14.

    Drug: Emraclidine · Drug: Placebo

  • Experimental
    Part B: Cohort 6: Emraclidine Dose 6

    Participants with dementia due to AD will receive emraclidine dose 6 or emraclidine-matching placebo tablets, orally, QD up to Day 28.

    Drug: Emraclidine · Drug: Placebo

Interventions

  • Oral tablets

    Also known as: CVL-231, PF-06852231

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Day 28

  2. Part A: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    Time frame: Up to Day 17

  3. Part A: Number of Participants With Clinically Significant Changes in Laboratory Assessments

    Time frame: Up to Day 17

  4. Part A: Number of Participants With Clinically Significant Changes in Vital Sign Measurements

    Time frame: Up to Day 17

  5. Part A: Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results

    Time frame: Up to Day 17

  6. Part A: Changes in Suicidality Assessed Using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.

    Time frame: Up to Day 17

  7. Part A: Number of Participants With Clinically Significant Findings in Extrapyramidal Symptoms Evaluated Using the Simpson Angus Scale (SAS)

    The SAS consists of a list of 10 symptoms of parkinsonism. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms and a score of 4 representing a severe condition. The SAS total score is the sum of the scores for all 10 items.

    Time frame: Up to Day 14

  8. Part A: Number of Participants With Clinically Significant Findings in Extrapyramidal Symptoms Evaluated Using the Abnormal Involuntary Movement Scale (AIMS)

    The AIMS assessment consists of 10 items describing symptoms of dyskinesia. Each item is rated on a 5-point scale, with a score of 0 representing absence of symptoms (for item 10, no awareness), and a score of 4 indicating a severe condition (for item 10, awareness, severe distress). In addition, the AIMS includes 2 yes/no questions that address the participant's dental status.

    Time frame: Up to Day 14

  9. Part A: Number of Participants With Clinically Significant Findings in Extrapyramidal Symptoms Evaluated Using the Barnes Akathisia Rating Scale (BARS)

    The BARS consists of 4 items related to akathisia. The first 3 items are rated on a 4-point scale, with a score of 0 representing absence of symptoms and a score of 3 representing a severe condition. The global clinical evaluation is made on a 6-point scale, with a score of 0 representing absence of symptom and a score of 5 representing severe akathisia.

    Time frame: Up to Day 14

  10. Part B: Number of Participants With TEAEs, Clinically Significant Changes in ECG Parameters, Laboratory Assessments, Vital Sign Measurements, and Physical and Neurological Examination Results

    Time frame: Up to Day 28

  11. Part B: Changes in Suicidality Assessed Using the C-SSRS

    Time frame: Up to Day 28

  12. Part B: Number of Participants With Clinically Significant Findings in Extrapyramidal Symptoms

    Extrapyramidal symptoms will be evaluated using SAS, AIMS, and BARS scales.

    Time frame: Up to Day 28

Secondary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of Emraclidine and its Metabolite CV-0000364

    Time frame: Days 1 and 14

  2. Part A: Time to Maximum Plasma Concentration (Tmax) of Emraclidine and its Metabolite CV-0000364

    Time frame: Days 1 and 14

  3. Part A: Area Under the Plasma Concentration-time Curve (AUC) of Emraclidine and its Metabolite CV-0000364

    Time frame: Days 1 and 14

  4. Part A: Trough Plasma Concentration (Ctrough) of Emraclidine and its Metabolite CV-0000364

    Time frame: Days 1 and 14

  5. Part A: Peak to Trough Ratio (PTR) of Emraclidine and its Metabolite CV-0000364

    Time frame: Day 14

  6. Part A: Apparent Clearance of Drug From Plasma (CL/F) of Emraclidine

    Time frame: Days 1 and 14

  7. Part A: Apparent Volume of Distribution During Terminal Phase (Vz/F) of Emraclidine

    Time frame: Days 1 and 14

  8. Part A: Apparent Terminal Half-life (t1/2) of Emraclidine and its Metabolite CV-0000364

    Time frame: Days 1 and 14

  9. Part A: Accumulation Ratio (Rac) of Emraclidine and its Metabolite CV-0000364

    Rac would be calculated from AUC and Cmax of emraclidine and its metabolite.

    Time frame: Day 14

  10. Part A: Metabolite to Parent Ratio of Emraclidine and its Metabolite CV-0000364

    Time frame: Days 1 and 14

  11. Part B: Plasma Concentrations of Emraclidine and its Metabolite CV-0000364

    Time frame: Days 1 to 28

07

Study locations

11 sites
  • Cypress, California
    Cypress, California 90630, United States
  • San Diego, California
    San Diego, California 92103, United States
  • Hialeah, Florida
    Hialeah, Florida 33014, United States
  • Decatur, Georgia
    Decatur, Georgia 30030, United States
  • Honolulu, Hawaii
    Honolulu, Hawaii 96817, United States
  • Overland Park, Kansas
    Overland Park, Kansas 66212, United States
  • Farmington Hills, Michigan
    Farmington Hills, Michigan 48334, United States
  • Marlton, New Jersey
    Marlton, New Jersey 08053, United States
  • Princeton, New Jersey
    Princeton, New Jersey 08540, United States
  • Staten Island, New York
    Staten Island, New York 10314, United States
  • North Canton, Ohio
    North Canton, Ohio 44720, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Apr 2025, 28 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 28 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartActual
Dec 2, 2022
Primary completionActual
Apr 14, 2025
CompletionActual
Apr 14, 2025
Last update
May 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05644977
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Dec 2, 2022
Primary completion
Apr 14, 2025
Completion
Apr 14, 2025
Last update
May 2, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emraclidine

Start the discussion